ERBB2 and breast carcinoma: Recent studies have applied deep learning algorithms to develop AI models for assisting various quantitative biomarker assessments, including HER2, Ki67 in breast cancer (25–27), and PD-L1 in lung cancer (14, 28), aiming to improve accuracy and reproducibility.